Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction

Annals of Medicine

Volumn 41, Issue 8, 2009, Pages 608-618

  Jessani, Shahirose S ^a   Lane, Deirdre A ^a   Shantsila, Eduard ^a   Watson, Timothy ^a   Millane, Teri A ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Acute myocardial infarction; Cardiovascular disease; Circulating endothelial cells; Diabetes mellitus; Impaired glucose tolerance; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; UMBILICAL VEINS; VON WILLEBRAND FACTOR;

EID: 72949118726     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890903159256     Document Type: Article

References (43)

1. Norhammar A, Tenerz A, Nilson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140.
2. Meier JJ, Deifuss S, Gallwitz B, Klamann A, Schmiegel W, Nauck MA. Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction. Dtsch Med Wochenschr. 2002;127:1123-1129
3. Choi MK, Lee WK, Kim GS, Kim HN, Park GC, Seo SH et al. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab. 2005;90:175-180
4. Hashimoto K, Ikewaki K, Yagi H, Nagasawa H, Imamoto S, Shibata T, et al. Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. Diabetes Care. 2005;28:1182-1186
5. Ramachandran A, Shanmugam MR, Chamukuttan S, Vis-wanathan V, Immaneni S, Jaakko T. High incidence of glucose intolerance in Asian-Indian subjects with acute coronary syndrome. Diabetes Care. 2005;28:2492-2496
6. Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, et al. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J. 2007;71:834-841
7. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Euro Heart J. 2004;25:1990-1997
8. Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006;22:198-203.
9. Oyama T, Miyasita Y, Watanabe H, Shirai K. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract. 2006;73:227-234
10. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis. 2000;11:623-630
11. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium. The first 30 years. Thromb Haemost. 2006;95:49-55.
12. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndrome. Circulation. 2008;117:1449-1459
13. Sakai H, Goto S, Kim JY, Aoki N, Abe S, Ichikawa N, et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84:204-209
14. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol. 2000;65:215-220 (Pubitemid 30760337)
15. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, inter-leukin-6, and prognosis in patients with acute coronary syndromes. Blood. 2005;105:526-532
16. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502-1513
17. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91 suppl 5:v1-52.
18. Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15: 539-553
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20: 1183-1197
20. Woywodt A, Goldberg C, Scheer J, Regelsberger H, Haller H, Haubitz M. An improved assay for enumeration of circulating endothelial cells. Ann Hematol. 2004;83:491.
21. Boos CJ, Lane DA, Kang D, Goon PK, Blann AD, Lip GY. Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. Thromb Thrombolysis. 2006;22:125-131
22. Leurs PB, Stolk RP, Hamulyak K, Oerle R, Grobbee DE, Wolffenbuttel BHR. Tissue factor pathway inhibitor and other endothelium-dependent haemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2002;25:1340-1345
23. Ceriello A. Acute hyperglycaemia and oxidative stress generation. Diabet Med. 1997;14(Suppl 3):S45-9.
24. Singleton JR, Smith AG, Russel WJ, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52:2867-2873
25. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47: 859-866
26. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: a review. Diabetologia. 2001;44:129-136
27. Van Oostorm AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ, Rabelink TJ, et al. Postprandial recruitment of neutrophils may contribute to endothelial function. J Lipid Res. 2003;44:576-583
28. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med. 2000;17:835-840
29. Temelkova-Kurktschiev TS, Koehler C, Schaper F, Leon-hardt W, Henkel H, Hanefeld M. Post challenge plasma glucose and glycaemic spikes are more strongly associated with atherosclerosis than fasting glucose and HbA1c. Diabetes Care. 2000;23:1830.
30. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglyaemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation. 2004;110: 214-219
31. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecules 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance*the Chennai Urban Rural Epidemilogy Study (CURES). Metabolism. 2006;55:1232-1238
32. Fritsche A, Haring H, Stumvoll M. White blood cell count as a predictor of glucose tolerance and insulin sensitivity. The role of inflammation in the pathogenesis of type 2 diabetes mellitus. Dtsch Med Wochenschr. 2004;129:244-248
33. Jessani S, Gangopadhyay K, Patel VJ, Lip GYH, Millane T Should oral glucose tolerance be mandatory following acute myocardial infarction? Int J Clin Pract. 2007;61:680-683
34. Ryden L, Standl E, Bartnik M, Van den Berghe E, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
35. Ramaiya KL, Swai ABM, Alberti KG, McLarty D. Lifestyle changes decrease rates of glucose intolerance and cardiovascular (CVD) risk factors: a six intervention study in a high risk Hindu Indian sub-community. Diabetologia. 1992; 35(suppl 1):A60.
36. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGTand Diabetes study. Diabetes Care. 1997;20:537-544
37. The DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355: 1551-1562
38. Hiralal R, Koo KY, Gerstein HC. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes? CMAJ. 2006;174:1090-1091
39. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; for the RIO-Europe Study Group. Effects of the cannabi-noid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in over weight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365:1389-1397 (Pubitemid 40523733)
40. Rendell MS, Jovanovic L. Targeting post prandial hyperglycaemia. Metabolism. 2006;55:1263-1281
41. Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L, et al. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care. 2003;26: 2770-2776
42. Boos CJ, Balakrishnan B, Blann AD, Lip GYH. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: Implications for prognosis. J Thromb Haemost. 2008;6:1841-1850
43. Lee KW, Blann AD, Lip GYH. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow mediated dilatation] to tissue factor in acute coronary syndromes. Int J Cardiol. 2006;111:302-308